Regarding the CCR2/CCL2 and CCR5/CCL5 systems, an oral dual CCR2/CCR5 antagonist, cenicriviroc (CVC), has been developed and is currently being evaluated in NASH patients. The gene discussed is CCL5; the disease is metabolic dysfunction-associated steatohepatitis.